Nonalcoholic steatohepatitis-related hepatocellular carcinoma: is there a role for the androgen receptor pathway?

References

• FerlayJShinHRBrayFFormanDMathersCParkinDMEstimates of worldwide burden of cancer in 2008: GLOBOCAN 2008Int J Cancer2010127122893291721351269
   PubMed Web of Science ®Google Scholar
• El-SeragHBLauMEschbachKDavilaJGoodwinJEpidemiology of hepatocellular carcinoma in hispanics in the United StatesArch Intern Med2007167181983198917923599
   PubMedGoogle Scholar
• WelzelTMGraubardBIZeuzemSEl-SeragHBDavilaJAMcGlynnKAMetabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare databaseHepatology (Baltimore, Md)2011542463471
   PubMed Web of Science ®Google Scholar
• BaffyGBruntEMCaldwellSHHepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menaceJ Hepatol20125661384139122326465
   PubMed Web of Science ®Google Scholar
• TateishiROkanoueTFujiwaraNClinical characteristics, treatment, and prognosis of non-B, non-C hepatocellular carcinoma: a large retrospective multicenter cohort studyJ Gastroenterol201550335036024929638
   PubMed Web of Science ®Google Scholar
• WhiteDLKanwalFEl-SeragHBAssociation between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic reviewClin Gastroenterol Hepatol2012101213421359.e223041539
   PubMed Web of Science ®Google Scholar
• FacciorussoAThe influence of diabetes in the pathogenesis and the clinical course of hepatocellular carcinoma: recent findings and new perspectivesCurr Diabetes Rev20139538238623845075
   PubMedGoogle Scholar
• TokushigeKHashimotoEKodamaKHepatocarcinogenesis in nonalcoholic fatty liver disease in JapanJ Gastroenterol Hepatol201328Suppl 4889224251711
   PubMed Web of Science ®Google Scholar
• WelzelTMGraubardBIQuraishiSPopulation-attributable fractions of risk factors for hepatocellular carcinoma in the United StatesAm J Gastroenterol201310881314132123752878
   PubMed Web of Science ®Google Scholar
• HefaiedhREnnaiferRRomdhaneHGender difference in patients with hepatocellular carcinomaTunis Med2013918–950550824227507
   PubMedGoogle Scholar
• El-SeragHBHepatocellular carcinomaN Engl J Med2011365121118112721992124
   PubMed Web of Science ®Google Scholar
• YamashitaYIYoshidaYKuriharaTSurgical results for recurrent hepatocellular carcinoma after curative hepatectomy: repeat hepatectomy vs. salvage living donor liver transplantationLiver Transpl201521796196825772591
   PubMedGoogle Scholar
• LlovetJMRicciSMazzaferroVSorafenib in advanced hepatocellular carcinomaN Engl J Med2008359437839018650514
   PubMed Web of Science ®Google Scholar
• LeeDHLeeJMLeeJYKimSHHanJKChoiBIRadiofrequency ablation for intrahepatic recurrent hepatocellular carcinoma: long-term results and prognostic factors in 168 patients with cirrhosisCardiovascu Intervent Radiol2014373705715
   PubMedGoogle Scholar
• CazanaveSCMottJLElmiNAJNK1-dependent PUMA expression contributes to hepatocyte lipoapoptosisJ Biol Chem200928439265912660219638343
   PubMed Web of Science ®Google Scholar
• AnguloPNonalcoholic fatty liver diseaseN Engl J Med2002346161221123111961152
   PubMed Web of Science ®Google Scholar
• AlbertiKGZimmetPZDefinition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultationDiabet Med19981575395539686693
   PubMed Web of Science ®Google Scholar
• GrundySMCleemanJIDanielsSRAmerican Heart AssociationNational Heart, Lung, and Blood InstituteDiagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific StatementCirculation2005112172735275216157765
   PubMed Web of Science ®Google Scholar
• AlbertiKGZimmetPShawJMetabolic syndrome – a new worldwide definition. A consensus statement from the international diabetes federationDiabet Med200623546948016681555
   PubMed Web of Science ®Google Scholar
• IsomaaBAlmgrenPTuomiTCardiovascular morbidity and mortality associated with the metabolic syndromeDiabetes Care200124468368911315831
   PubMed Web of Science ®Google Scholar
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in AdultsExecutive summary of the third report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III)JAMA2001285192486249711368702
   PubMed Web of Science ®Google Scholar
• EssahPANestlerJEThe metabolic syndrome in polycystic ovary syndromeJ Endocrinol Invest200629327028016682845
   PubMed Web of Science ®Google Scholar
• LonardoABallestriSMarchesiniGAnguloPLoriaPNonalcoholic fatty liver disease: a precursor of the metabolic syndromeDig Liver Dis201547318119025739820
   PubMedGoogle Scholar
• ByrneCDOlufadiRBruceKDCagampangFRAhmedMHMetabolic disturbances in non-alcoholic fatty liver diseaseClin Sci (Lond)2009116753956419243311
   PubMed Web of Science ®Google Scholar
• RinellaMENonalcoholic fatty liver disease: a systematic reviewJAMA2015313222263227326057287
   PubMed Web of Science ®Google Scholar
• KubesPMehalWZSterile inflammation in the liverGastroenterology201214351158117222982943
   PubMed Web of Science ®Google Scholar
• WiegandJMossnerJTillmannHLNon-alcoholic fatty liver disease and non-alcoholic steatohepatitisDer Internist2007482154163 German17226007
   PubMedGoogle Scholar
• TomimaruYKogaHYanoHde la MonteSWandsJRKimMUpregulation of T-cell factor-4 isoform-responsive target genes in hepatocellular carcinomaLiver Int20133371100111223651211
   PubMedGoogle Scholar
• BianZMaXLiver fibrogenesis in non-alcoholic steatohepatitisFront Physiol2012324822934006
   PubMedGoogle Scholar
• WuJZhangJShenBLong noncoding RNA lncTCF7, induced by IL-6/STAT3 transactivation, promotes hepatocellular carcinoma aggressiveness through epithelial-mesenchymal transitionJ Exp Clin Cancer Res20153411626452542
   PubMedGoogle Scholar
• JungIHChoiJHChungYYLimGLParkYNParkSWPredominant activation of JAK/STAT3 pathway by Interleukin-6 is implicated in hepatocarcinogenesisNeoplasia201517758659726297436
   PubMedGoogle Scholar
• WanSZhaoEKryczekITumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cellsGastroenterology201414761393140425181692
   PubMed Web of Science ®Google Scholar
• BugianesiEPagottoUManiniRPlasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severityJ Clin Endocrinol Metab20059063498350415797948
   PubMed Web of Science ®Google Scholar
• MussoGGambinoRDurazzoMAdipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver diseaseHepatology20054251175118316231364
   PubMedGoogle Scholar
• DingXSaxenaNKLinSXuASrinivasanSAnaniaFAThe roles of leptin and adiponectin: a novel paradigm in adipocytokine regulation of liver fibrosis and stellate cell biologyAm J Pathol200516661655166915920151
   PubMed Web of Science ®Google Scholar
• ParkEJLeeJHYuGYDietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expressionCell2010140219720820141834
   PubMed Web of Science ®Google Scholar
• AwazawaMUekiKInabeKAdiponectin suppresses hepatic SREBP1c expression in an AdipoR1/LKB1/AMPK dependent pathwayBiochem Biophys Res Commun20093821515619254698
   PubMed Web of Science ®Google Scholar
• IkejimaKOkumuraKKonKTakeiYSatoNRole of adipocytokines in hepatic fibrogenesisJ Gastroenterol Hepatol200722Suppl 1S87S9217567476
   PubMedGoogle Scholar
• WestonSRLeydenWMurphyRRacial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver diseaseHepatology200541237237915723436
   PubMed Web of Science ®Google Scholar
• BaigSGender disparity in infections of hepatitis B virusJ Coll Physicians Surg Pak200919959860019728952
   PubMedGoogle Scholar
• BrowningJDSzczepaniakLSDobbinsRPrevalence of hepatic steatosis in an urban population in the United States: impact of ethnicityHepatology20044061387139515565570
   PubMed Web of Science ®Google Scholar
• BaconBRFarahvashMJJanneyCGNeuschwander-TetriBANonalcoholic steatohepatitis: an expanded clinical entityGastroenterology19941074110311097523217
   PubMedGoogle Scholar
• MarchesiniGBugianesiEForlaniGNonalcoholic fatty liver, steatohepatitis, and the metabolic syndromeHepatology200337491792312668987
   PubMed Web of Science ®Google Scholar
• AngelicoFDel BenMContiRNon-alcoholic fatty liver syndrome: a hepatic consequence of common metabolic diseasesJ Gastroenterol Hepatol200318558859412702052
   PubMedGoogle Scholar
• KralJGSchaffnerFPiersonRNJrWangJBody fat topography as an independent predictor of fatty liverMetabolism19934255485518492707
   PubMedGoogle Scholar
• OmagariKKadokawaYMasudaJFatty liver in non-alcoholic non-overweight Japanese adults: incidence and clinical characteristicsJ Gastroenterol Hepatol200217101098110512201871
   PubMed Web of Science ®Google Scholar
• KamadaYKisoSYoshidaYEstrogen deficiency worsens steatohepatitis in mice fed high-fat and high-cholesterol dietAm J Physiol Gastrointest Liver Physiol20113016G1031G104321885686
   PubMedGoogle Scholar
• PolyzosSAKountourasJTsatsoulisASex steroids and sex hormone-binding globulin in postmenopausal women with nonalcoholic fatty liver diseaseHormones201312340541624121382
   PubMedGoogle Scholar
• ShinJYKimSKLeeMYSerum sex hormone-binding globulin levels are independently associated with nonalcoholic fatty liver disease in people with type 2 diabetesDiabetes Res Clin Pract201194115616221862168
   PubMedGoogle Scholar
• VassilatouENonalcoholic fatty liver disease and polycystic ovary syndromeWorld J Gastroenterol201420268351836325024594
   PubMed Web of Science ®Google Scholar
• CiottaLPaganoIStracquadanioMFormusoCPolycystic ovarian syndrome incidence in young women with non-alcoholic fatty liver diseaseMinerva Ginecol2011635429437 Italian21926952
   PubMedGoogle Scholar
• NauglerWESakuraiTKimSGender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 productionScience2007317583412112417615358
   PubMed Web of Science ®Google Scholar
• PrietoJInflammation, HCC and sex: IL-6 in the centre of the triangleJ Hepatol200848238038118093689
   PubMedGoogle Scholar
• ZhangHLiuYWangLDifferential effects of estrogen/androgen on the prevention of nonalcoholic fatty liver disease in the male ratJ Lipid Res201354234535723175777
   PubMed Web of Science ®Google Scholar
• ChowJDJonesMEPrelleKSimpsonERBoonWCA selective estrogen receptor alpha agonist ameliorates hepatic steatosis in the male aromatase knockout mouseJ Endocrinol2011210332333421705395
   PubMedGoogle Scholar
• JonesHSprungVSPughCJPolycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistanceJ Clin Endocrinol Metab201297103709371622837189
   PubMedGoogle Scholar
• SchwingelPACotrimHPSallesBRAnabolic-androgenic steroids: a possible new risk factor of toxicant-associated fatty liver diseaseLiver Int201131334835321040407
   PubMed Web of Science ®Google Scholar
• HaiderASaadFDorosGGoorenLHypogonadal obese men with and without diabetes mellitus type 2 lose weight and show improvement in cardiovascular risk factors when treated with testosterone: an observational studyObes Res Clin Pract201484e339e34925091355
   PubMed Web of Science ®Google Scholar
• LinHYYuICWangRSIncreased hepatic steatosis and insulin resistance in mice lacking hepatic androgen receptorHepatology (Baltimore, Md)200847619241935
   PubMed Web of Science ®Google Scholar
• Moverare-SkrticSVenkenKAnderssonNDihydrotestosterone treatment results in obesity and altered lipid metabolism in orchidectomized miceObesity (Silver Spring, Md)2006144662672
   PubMed Web of Science ®Google Scholar
• NorlinMPetterssonHTangWWikvallKAndrogen receptor-mediated regulation of the anti-atherogenic enzyme CYP27A1 involves the JNK/c-jun pathwayArch Biochem Biophys2011506223664121134350
   PubMed Web of Science ®Google Scholar
• KrycerJRBrownAJCross-talk between the androgen receptor and the liver X receptor: implications for cholesterol homeostasisJ Biol Chem201128623206372064721489984
   PubMed Web of Science ®Google Scholar
• LonardoALoriaPPotential for statins in the chemoprevention and management of hepatocellular carcinomaJ Gastroenterol Hepatol201227111654166422849701
   PubMedGoogle Scholar
• LaiSWLiaoKFLaiHCMuoCHSungFCChenPCStatin use and risk of hepatocellular carcinomaEur J Epidemiol201328648549223681775
   PubMedGoogle Scholar
• TsanYTLeeCHWangJDChenPCStatins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infectionJ Clin Oncol201230662363022271485
   PubMed Web of Science ®Google Scholar
• El-SeragHBJohnsonMLHachemCMorganaROStatins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetesGastroenterology200913651601160819208359
   PubMedGoogle Scholar
• SinghSSinghPPSinghAGMuradMHSanchezWStatins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysisGastroenterology2013144232333223063971
   PubMed Web of Science ®Google Scholar
• WuCYChenYJHoHJHsuYCKuoKNWuMSAssociation between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resectionJAMA2012308181906191423162861
   PubMed Web of Science ®Google Scholar
• EmbersonJRKearneyPMBlackwellLCholesterol Treatment Trialists’ (CTT) CollaborationLack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapyPLoS One201271e2984922276132
   PubMed Web of Science ®Google Scholar
• ChangCHLinJWWuLCLaiMSChuangLMOral insulin secretagogues, insulin, and cancer risk in type 2 diabetes mellitusJ Clin Endocrinol Metab2012977E1170E117522563104
   PubMed Web of Science ®Google Scholar
• ChenHHLinMCMuoCHYehSYSungFCKaoCHCombination therapy of mtetformin and statin may decrease hepatocellular carcinoma among diabetic patients in AsiaMedicine20159424e101326091447
   PubMedGoogle Scholar
• ChenHPShiehJJChangCCMetformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studiesGut201362460661522773548
   PubMed Web of Science ®Google Scholar
• OkumuraTMechanisms by which thiazolidinediones induce anticancer effects in cancers in digestive organsJ Gastroenterol201045111097110220824291
   PubMedGoogle Scholar
• RuiterRVisserLEvan Herk-SukelMPLower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up studyDiabetes Care201235111912422100960
   PubMed Web of Science ®Google Scholar
• SinghSKheraRMuradMHLoombaRReplyHepatology (Baltimore, Md)2016642694
   PubMedGoogle Scholar
• EagonPKElmMSEpleyMJShinozukaHRaoKNSex steroid metabolism and receptor status in hepatic hyperplasia and cancer in ratsGastroenterology19961104119912078613010
   PubMedGoogle Scholar
• OstrowskiJLIngletonPMUnderwoodJCParsonsMAIncreased hepatic androgen receptor expression in female rats during diethylnitrosamine liver carcinogenesis. A possible correlation with liver tumor developmentGastroenterology1988945 Pt 1119312003350289
   PubMedGoogle Scholar
• TejuraSRodgersGRDunionMHParsonsMAUnderwoodJCIngletonPMSex-steroid receptors in the diethylnitrosamine model of hepatocarcinogenesis: modifications by gonadal ablation and steroid replacement therapyJ Mol Endocrinol1989332292372590384
   PubMedGoogle Scholar
• NakataniTRoyGFujimotoNAsaharaTItoASex hormone dependency of diethylnitrosamine-induced liver tumors in mice and chemo-prevention by leuprorelinJpn J Cancer Res200192324925611267934
   PubMedGoogle Scholar
• FengHChengASTsangDPCell cycle-related kinase is a direct androgen receptor-regulated gene that drives beta-catenin/T cell factor- dependent hepatocarcinogenesisJ Clin Invest201112183159317521747169
   PubMed Web of Science ®Google Scholar
• TianYWongVWChanHLChengASEpigenetic regulation of hepatocellular carcinoma in non-alcoholic fatty liver diseaseSemin Cancer Biol2013236 Pt B47148224018165
   PubMed Web of Science ®Google Scholar
• GelmannEPMolecular biology of the androgen receptorJ Clin Oncol200220133001301512089231
   PubMed Web of Science ®Google Scholar
• BoltonECSoAYChaivorapolCHaqqCMLiHYamamotoKRCell- and gene-specific regulation of primary target genes by the androgen receptorGenes Dev200721162005201717699749
   PubMed Web of Science ®Google Scholar
• CuligZAndrogen receptor coactivators in regulation of growth and differentiation in prostate cancerJ Cell Physiol2016231227027426201947
   PubMedGoogle Scholar
• AgoulnikIUWeigelNLCoactivator selective regulation of androgen receptor activitySteroids200974866967419463689
   PubMedGoogle Scholar
• KalraMMayesJAssefaSKaulAKKaulRRole of sex steroid receptors in pathobiology of hepatocellular carcinomaWorld J Gastroenterol200814395945596118932272
   PubMedGoogle Scholar
• NagasueNKohnoHChangYCAndrogen and estrogen receptors in hepatocellular carcinoma and the surrounding liver in womenCancer19896311121162535950
   PubMed Web of Science ®Google Scholar
• BoixLCastellsABruixJAndrogen receptors in hepatocellular carcinoma and surrounding liver: relationship with tumor size and recurrence rate after surgical resectionJ Hepatol19952266166227560855
   PubMed Web of Science ®Google Scholar
• ZhangXHeLLuYLiuMHuangXAndrogen receptor in primary hepatocellular carcinoma and its clinical significanceChin Med J1998111121083108611263369
   PubMedGoogle Scholar
• AoJMengJZhuLActivation of androgen receptor induces ID1 and promotes hepatocellular carcinoma cell migration and invasionMol Oncol20126550751522819717
   PubMed Web of Science ®Google Scholar
• MaWLJengLBLaiHCLiaoPYChangCAndrogen receptor enhances cell adhesion and decreases cell migration via modulating beta1-integrin-AKT signaling in hepatocellular carcinoma cellsCancer Lett20143511647124944078
   PubMedGoogle Scholar
• MaWLHsuCLYehCCHepatic androgen receptor suppresses hepatocellular carcinoma metastasis through modulation of cell migration and anoikisHepatology (Baltimore, Md)2012561176185
   PubMedGoogle Scholar
• ForbesAWilkinsonMLIqbalMJJohnsonPJWilliamsRResponse to cyproterone acetate treatment in primary hepatocellular carcinoma is related to fall in free 5 alpha-dihydrotestosteroneEur J Cancer Clin Oncol19872311165916642828073
   PubMedGoogle Scholar
• GuptaSKorulaJFailure of ketoconazole as anti-androgen therapy in nonresectable primary hepatocellular carcinomaJ Clin Gastroenterol19881066516542466073
   PubMed Web of Science ®Google Scholar
• ChaoYChanWKHuangYSPhase II study of flutamide in the treatment of hepatocellular carcinomaCancer19967746356398616754
   PubMed Web of Science ®Google Scholar
• GrimaldiCBleibergHGayFEvaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: results of a European Organization for Research and Treatment of Cancer multicentric double-blind trialJ Clin Oncol19981624114179469323
   PubMed Web of Science ®Google Scholar
• ManesisEKGiannoulisGZoumboulisPVafiadouIHadziyannisSJTreatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: a randomized, controlled trialHepatology (Baltimore, Md)199521615351542
   PubMed Web of Science ®Google Scholar
• Groupe d’Etude et de Traitement du Carcinome HépatocellulaireRandomized trial of leuprorelin and flutamide in male patients with hepatocellular carcinoma treated with tamoxifenHepatology (Baltimore, Md)200440613611369
   PubMedGoogle Scholar
• Di MaioMDe MaioEMorabitoAHormonal treatment of human hepatocellular carcinomaAnn N Y Acad Sci2006108925226117261772
   PubMedGoogle Scholar
• VillaECritelliRLeiBNeoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective studyGut201665586186925666192
   PubMed Web of Science ®Google Scholar
• WeiskirchenRIntratumor heterogeneity, variability and plasticity: questioning the current concepts in classification and treatment of hepatocellular carcinomaHepatobiliary Surg Nutr20165218318727115013
   PubMedGoogle Scholar
• LiLWangHHeterogeneity of liver cancer and personalized therapyCancer Lett2015379219119726213370
   PubMedGoogle Scholar
• HsuCHKangYKYangTSBevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: a multicenter phase II studyOncology2013851445223838576
   PubMed Web of Science ®Google Scholar
• CainapCQinSHuangWTLinifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trialJ Clin Oncol201533217217925488963
   PubMed Web of Science ®Google Scholar
• WelkerMWTrojanJAntiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safetyCancer Manag Res2013533734724204170
   PubMedGoogle Scholar
• GovindarajanRSiegelEMakhoulIWilliamsonSBevacizumab and erlotinib in previously untreated inoperable and metastatic hepatocellular carcinomaAm J Clin Oncol201336325425722643560
   PubMed Web of Science ®Google Scholar
• KasebAOGarrett-MayerEMorrisJSEfficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trialOncology2012822677422327795
   PubMed Web of Science ®Google Scholar
• PhilipPAMahoneyMRHolenKDPhase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancerCancer201211892424243021953248
   PubMed Web of Science ®Google Scholar
• YauTWongHChanPPhase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory diseaseInvest New Drugs20123062384239022402942
   PubMed Web of Science ®Google Scholar
• ThomasMBMorrisJSChadhaRPhase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinomaJ Clin Oncol200927684385019139433
   PubMed Web of Science ®Google Scholar
• JiangXKandaTNakamotoSMiyamuraTWuSYokosukaOInvolvement of androgen receptor and glucose-regulated protein 78 kDa in human hepatocarcinogenesisExp Cell Res2014323232633624583399
   PubMed Web of Science ®Google Scholar